


RECEIVED

MAR 04 2003

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/0896 10-96 OMB 0651-0050

TECH CENTER 1600/2900

Approved for use through 10/31/99 OMB 0651-0050

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

4

Complete if Known

Application Number	09/806,400
Filing Date	September 30, 1999
First Named Inventor	Shoenfeld et al
Group Art Unit	1644
Examiner Name	R. B. Schwadron
Attorney Docket Number	01/21885

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RPS	AE	Blanas, et al., Induction of Autoimmune Diabetes by Oral Administration of Autoantigen, Science, 274(5293): 1707-1712	
	AF	Peel, et al. LDI modifiees et atherosclerose, Nature des modifications. Proprietes physicochimiques et biologiques, Ann Biol Clin (1992), 50, 213-227	
WBS	AG	Mol, et al., The role of modification of lipoproteins and of the immune system in early atherogenesis, Netherlands Journal of Medicine, 43 (1993) 83-90	
	AH	Hoff, et al., Structure of cholesterol-containing particles accumulating in atherosclerotic lesions and the mechanisms of their derivation, Current Opinion in Lipidology 1995, 6:317-325	
	AI	Shen, et al., From interaction of lipidic vehicles with intestinal epithelial cell membranes to the formation and secretion of chylomicrons, Advanced Drug Delivery Reviews, 50 (2001) S103-S125	
	AJ	Maurer, et al., Developments in liposomal drug delivery systems, Expert Opin. Biol. Ther. (2001) 1(6) pp 1-25	
	AK	Emeson et al., Accelerated Atherosclerosis in Hyperlipidemic C57BL/6 Mice Treated with Cyclosporin A, American Journal of Pathology, Vol. 142, No. 6, June 1993, pp. 1906-1915	
	AL	Meir et al., Inflammation in atherosclerosis - causal or casual? Dept. Pathology (K.M.), the Center for Research, Prevention and Treatment of Atherosclerosis, pp. 1-5	
↓	AM	Williams, et al., Rodent models of arthritis: relevance for human disease, Clin. Exp. Immunol. 1998: 114:330-332	

Examiner Signature

R. B. Schwadron

Date Considered

5/14/2003

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

MAR 04 2003

Please type a plus sign (+) inside this box →

FEB 27 2003

PTO/SB/06A (10-96)

REENTER 1600/2900

Approved for use through 10/31/99 GPO: 2003 OMB Control Number 1010-0003

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	3	of	4	Application Number	09/806,400
				Filing Date	September 30, 1999
				First Named Inventor	Shoenfeld et al
				Group Art Unit	1644
				Examiner Name	R. B. Schwadron
				Attorney Docket Number	01/21885

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
WB	AN	Fujinami, et al., Myelin Basic Protein Serum Factor: An Endogenous Neuroantigen Influencing Development of Experimental Allergic Encephalomyelitis in Lewis Rats, <i>Brief Definitive Report</i> , J. Exp. Med., Vol. 148, December 1978, pp. 1716-1721			
	AO	Ogra et al., Vaccination Strategies for Mucosal Immune Response, Clinical Microbiology Reviews, Vol. 14, No. 2, Apr. 2001, pp. 430-445			
	AP	Lehner et al., The Effect of Route of Immunization on Mucosal Immunity and Protection, The Journal of Infectious Diseases, 1999;179(Suppl 3):S489-S492			
	AQ	Chen, Recent advances in mucosal vaccine development, Journal of Controlled Release 67 (2000) pp. 117-128			
	AR	Palinski, et al., Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherosclerosis, Proc. Natl. Acad. Sci. USA, Vol. 92, January 1995, pp. 821-825			
	AS	George et al., Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherosclerosis, Atherosclerosis 138 (1998) pp. 147-152			
	AT	Freigang, et al., Immunization of LDL Receptor-Deficient Mice with Homologous Malondialdehyde-Modified and Native LDL Reduces Progression of Atherosclerosis by Mechanisms Other Than Induction of High Titers of Antibodies to Oxidative Neoepitopes, Arterioscler Thromb Vasc Biol, December 1998, pp. 1972 –1982			

Examiner Signature	<i>[Signature]</i>	Date Considered	5/14/2003
--------------------	--------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

MAR 04 2003



Please type a plus sign (+) inside this box →

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TECH CENTER 1600/2900


PTO/SB/08A (T0-96)

Approved for use through 10/31/99 OMB 0651-0031

**PATENT AND TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p style="text-align: center;">Substitute for form 1449A/PTO</p> <p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center;"><i>(use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	09/806,400
				Filing Date	September 30, 1999
				First Named Inventor	Shoenfeld et al
				Group Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	4	of	4	Attorney Docket Number	
01/21885					

Examiner Signature  **Date Considered** 5/14/2013

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.